Revenue guidance for 2026 is revised to €2.1–2.16 billion and EBITDA to €88–92 million, mainly due to price pressure in pharmaceutical supply and regulatory changes impacting cannabis margins. Operational excellence initiatives, including site closures and cost optimization, are expected to improve margins, especially in patient-specific therapies.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.